Potent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450nM), CDK2 (IC50 = 700nM) and CDK5/p35 (IC50 = 160nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 and NF-kappaB pathways. Has effects on calcium channel gating. Prevents DNA damage-induced cyclin A1 upregulation. Apoptosis inducer. As CYC202 in phase I clinical trials. Synonyms: (2R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol, (R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol, 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, CYC 202, (R)-Roscovitine, R-Roscovitine, Roscovitin, Seliciclib CAS Number: 186692-46-6 Molecular Weight: 354.5 Molecular Formula: C19H26N6O Solubility: DMSO or 100% ethanol, only moderately soluble in water Appearance: Supplied as a white to off-white solid. Purity: 98% (NMR) Storage and Stability: Store at 4C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molekulargewicht:
354.5
Reinheit:
98% (NMR)
Formulierung:
Supplied as a white to off-white solid.
CAS Nummer:
[186692-46-6]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten